Ovariancancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer. (NCT07339553) | Peking University Third Hospital | 2026-01-04 |
Track Ovariancancer automatically
Every clearance here is in the API, with alerts when new ones post.